Browsing by Author Given, B

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 中
Showing results 1 to 8 of 8
TitleAuthor(s)Issue Date
 
A phase 1 study to evaluate safety and tolerability of escalating single doses of the hepatitis B virus RNA interference drug ARC-521 in a healthy volunteer population
Proceeding/Conference:Journal of Hepatology
Gane, ESchwabe, CGiven, BSchluep, THamilton, JLai, CLLocarnini, SLau, JFerrari, CGish, R
2017
 
First clinical experience with RNA interference [RNAI]-based triple combination therapy in chronic hepatitis B (CHB): JNJ-73763989 (JNJ-3989), JNJ-56136379 (JNJ-6379) and a nucleos(t)ide analogue (NA)
Proceeding/Conference:Hepatology
Yuen, RMFLocarnini, SGiven, BSchluep, THamilton, JBiermer, MKalmeijer, RBeumont-Mauviel, MLenz, OCloherty, GJackson, KFerrari, CLai, CLLiu, SHKMak, LYWong, DKHTo, WPKo, KLGish, RG
2019
 
First results with RNA interference (RNAi) in chronic hepatitis b (CHB) using ARO-HBV
Proceeding/Conference:Hepatology
Gane, EJLocarnini, SLim, THStrasser, SSievert, WCheng, WThompson, AGiven, BSchluep, THamilton, JLi, ZCloherty, GWong, DKHSchwabe, CJackson, KFerrari, CLai, CLGish, RGYuen, RMF
2018
 
Predicting HBsAg clearance responses during ARC-520 RNA interference (RNAi) therapy based on HBsAg epitope profile analysis
Proceeding/Conference:Journal of Hepatology
Walsh, RYuen, LHammond, RDeerain, JGiven, BSchluep, TYuen, MFChan, HLYLai, CLHamilton, JLau, JYFerrari, CGish, RGLocarnini, SA
2016
 
RNA interference therapy with ARC-520 Injection results in long term off-therapy antigen reductions in treatment naïve, HBeAg positive and negative patients with chronic HBV
Proceeding/Conference:Journal of Hepatology
Yuen, RMFLiu, SHKGiven, BSchluep, THamilton, JLai, CLLocarnini, SJackson, KLai, JYFerrari, CGish, RG.
2018
 
Short interfering RNA JNJ-3989 combination therapy in chronic hepatitis B shows potent reduction of all viral markers but no correlate was identified for HBsAg reduction and baseline factors
Proceeding/Conference:Journal of Hepatology
Gane, ELocarnini, SLim, THStrasser, SSievert, WCheng, WThompson, AGiven, BSchluep, THamilton, JBiermer, MKalmeijer, RBeumont-Mauviel, MLenz, ODe Ridder, FCloherty, GWong, DKHSchwabe, CJackson, KFerrari, CLai, CLGish, RGYuen, RMF
2021
 
Short term RNA interference therapy in chronic hepatitis B using JNJ-3989 brings majority of patients to HBsAg < 100 IU/ml threshold
Proceeding/Conference:Journal of Hepatology
Yuen, RMFLocarnini, SLim, THStrasser, SSievert, WCheng, WThompson, AGiven, BSchluep, THamilton, JCloherty, GWong, DKHSchwabe, CJackson, KFerrari, CLai, CLGish, RGGane, E
2019
 
Short-term treatment with RNA interference therapy, JNJ-3989, results in sustained hepatitis B surface antigen suppression in patients with chronic hepatitis B receiving nucleos(t)ide analogue treatment
Proceeding/Conference:Journal of Hepatology
Gane, ELocarnini, SLim, THStrasser, SSievert, WCheng, WThompson, AGiven, BSchluep, THamilton, JBiermer, MKalmeijer, RBeumont-Mauviel, MLenz, OCloherty, GWong, DKHSchwabe, CJackson, KFerrari, CLai, CLGish, RGYuen, RMF
2020
Showing results 1 to 8 of 8